相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies
Paolo Lanzetta et al.
ACTA OPHTHALMOLOGICA (2018)
Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study
Katja Hatz et al.
ACTA OPHTHALMOLOGICA (2017)
Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register
Inger Westborg et al.
ACTA OPHTHALMOLOGICA (2017)
UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice
Aaron Y. Lee et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age related macular degeneration
Raimo Tuuminen et al.
ACTA OPHTHALMOLOGICA (2017)
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
Robert L. Johnston et al.
ADVANCES IN THERAPY (2017)
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
David Chin-Yee et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration - a population- and register-based study from northern Sweden
Elisabet Granstam et al.
ACTA OPHTHALMOLOGICA (2016)
Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials
Sebastian M. Waldstein et al.
OPHTHALMOLOGY (2016)
Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration
Annette Rasmussen et al.
ACTA OPHTHALMOLOGICA (2015)
Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
Karina Berg et al.
OPHTHALMOLOGY (2015)
Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration Leads to Vision Loss in Treatment of Neovascular Age-Related Macular Degeneration
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010
Rupert R. A. Bourne et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
Allen C. Ho et al.
OPHTHALMOLOGY (2014)
Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
Gui-shuang Ying et al.
OPHTHALMOLOGY (2013)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
Lars Hjelmqvist et al.
JOURNAL OF OPHTHALMOLOGY (2011)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
